drugset / Trial / NCT04172441

Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

NCT04172441

Phase 2/3 Completed 12 enrolled Zealand Pharma
RandomizedCrossoverQuadruple-blindTreatment

Summary

The objective of the trial is to evaluate the efficacy of dasiglucagon in reducing glucose requirements in children with persistent congenital hyperinsulinism (CHI) requiring continuous intravenous (IV) glucose administration to prevent/manage hypoglycemia.

Timeline

Start
2020-06-19
Primary completion
2022-02-17
Completion
2022-03-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Dasiglucagon Peptide 10 ug Subcutaneous